File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Continuation rate of hormone replacement therapy in Hong Kong public health sector

TitleContinuation rate of hormone replacement therapy in Hong Kong public health sector
Authors
KeywordsCompliance
Hong Kong
Hormone replacement therapy
Menopause
Issue Date2004
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitas
Citation
Maturitas, 2004, v. 49 n. 4, p. 338-344 How to Cite?
AbstractObjectives: To assess the 1-year continuation rate of HRT prescribed in Hong Kong public health sector and to identify factors affecting this continuation rate. Methods: All women who received at least one dispensed prescription of estrogens between January 1998 and December 2000 from 36 specialist outpatient clinics of the Hospital Authority were selected, and observed for at least 2 years and at most 3 years. The duration of use and variables including age, types of hormones, routes of delivery, dose of estrogen, and prescribing specialty were retrieved from the central prescription database of the Hospital Authority. Results: Of 12,711 incident users of HRT, more than half were aged 50-59. Most (78.5%) of the users took conjugated equine estrogens (CEE) 0.625 mg or related products. Only a small proportion (3.0%) of women used CEE 0.3 mg. Initial estrogen prescriptions were written by gynaecologists in 86.7%. The overall 1-year continuation rate was 68.3%. The highest and lowest continuation rates were observed in women aged 40-49 and the two extreme age groups (35-39 and 70-79), respectively. Better continuation rate was observed in women taking estrogen-only therapy such as CEE or estradiol (overall 76.3%) than in women using continuous combined therapy (58.6%), sequential combined therapy (64.8%), or transdermal estrogen (60.6%). In the age group 60-69, the use of CEE 0.3 mg was associated with better continuation rate than CEE 0.625 mg. Conclusions: Better continuation rate at 1 year was associated with age younger than 60, oral route of HRT and hysterectomy. © 2004 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/87390
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.280
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, KYen_HK
dc.contributor.authorLing, Men_HK
dc.contributor.authorTang, GWKen_HK
dc.date.accessioned2010-09-06T09:29:03Z-
dc.date.available2010-09-06T09:29:03Z-
dc.date.issued2004en_HK
dc.identifier.citationMaturitas, 2004, v. 49 n. 4, p. 338-344en_HK
dc.identifier.issn0378-5122en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87390-
dc.description.abstractObjectives: To assess the 1-year continuation rate of HRT prescribed in Hong Kong public health sector and to identify factors affecting this continuation rate. Methods: All women who received at least one dispensed prescription of estrogens between January 1998 and December 2000 from 36 specialist outpatient clinics of the Hospital Authority were selected, and observed for at least 2 years and at most 3 years. The duration of use and variables including age, types of hormones, routes of delivery, dose of estrogen, and prescribing specialty were retrieved from the central prescription database of the Hospital Authority. Results: Of 12,711 incident users of HRT, more than half were aged 50-59. Most (78.5%) of the users took conjugated equine estrogens (CEE) 0.625 mg or related products. Only a small proportion (3.0%) of women used CEE 0.3 mg. Initial estrogen prescriptions were written by gynaecologists in 86.7%. The overall 1-year continuation rate was 68.3%. The highest and lowest continuation rates were observed in women aged 40-49 and the two extreme age groups (35-39 and 70-79), respectively. Better continuation rate was observed in women taking estrogen-only therapy such as CEE or estradiol (overall 76.3%) than in women using continuous combined therapy (58.6%), sequential combined therapy (64.8%), or transdermal estrogen (60.6%). In the age group 60-69, the use of CEE 0.3 mg was associated with better continuation rate than CEE 0.625 mg. Conclusions: Better continuation rate at 1 year was associated with age younger than 60, oral route of HRT and hysterectomy. © 2004 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/maturitasen_HK
dc.relation.ispartofMaturitasen_HK
dc.rightsMaturitas. Copyright © Elsevier Ireland Ltd.en_HK
dc.subjectComplianceen_HK
dc.subjectHong Kongen_HK
dc.subjectHormone replacement therapyen_HK
dc.subjectMenopauseen_HK
dc.titleContinuation rate of hormone replacement therapy in Hong Kong public health sectoren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0378-5122&volume=49&spage=338&epage=344&date=2004&atitle=Continuation+rate+of+hormone+replacement+therapy+in+Hong+Kong+public+health+sectoren_HK
dc.identifier.emailTang, GWK:gwktang@hkucc.hku.hken_HK
dc.identifier.authorityTang, GWK=rp00328en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.maturitas.2004.03.010en_HK
dc.identifier.pmid15531131en_HK
dc.identifier.scopuseid_2-s2.0-8644236706en_HK
dc.identifier.hkuros96765en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8644236706&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume49en_HK
dc.identifier.issue4en_HK
dc.identifier.spage338en_HK
dc.identifier.epage344en_HK
dc.identifier.isiWOS:000225370500010-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridLeung, KY=8247106900en_HK
dc.identifier.scopusauthoridLing, M=16552664600en_HK
dc.identifier.scopusauthoridTang, GWK=7401633864en_HK
dc.identifier.issnl0378-5122-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats